In Pursuit of Sustainable Development of Talents and Products
Corporate Social Responsibility Honors and Ratings
- 2022 Corporate Social Responsibility Report Rating: Excellent
- 2022 Technology Responsibility - Pioneer 30 Index List
- Annual Enterprise of Corporate Social Responsibility Award from People.cn
- 2022 Fortune China ESG Impact List
- ESG Competitiveness Top 20 among Chinese Listed Pharmaceutical Enterprises for 2022
- 2022 Green Star for Excellence in ESG Performance
- "Most Socially Responsible Listed Company"in the 12th Chinese Company Reputation List for 2022
Our Stories
-
-
Hand in Hand- Rural Medical Talent Vitalization Plan
-
Hand in Hand- Rural Medical Talent Vitalization Plan
In order to better assist rural vitalization, the "Fosun Care 121" Special Fund has launched the "Hand in Hand Rural Medical Talent Vitalization Plan" with the vast number of rural doctors as the target group. The plan includes "Four Ones", that is, a Pocket Book for Rural Doctors' Diagnosis and Treatment, a cloud guardian platform for rural doctors, a group of health care ambassador hand in hand assistance through online consultation, aiming to combine online and offline ways to help rural doctors master the expertise relating to diagnosis and treatment and health management, and obtain the timely and effective answers to the diagnosis and treatment.
-
-
-
Run for “TOGETHER WE BUILD A MALARIA-FREE WORLD” Charity Campaign
-
Run for “TOGETHER WE BUILD A MALARIA-FREE WORLD” Charity Campaign
On April 25, 2023, starting from Guilin, China, more than 1,600 employees from Fosun family companied in Cote d 'Ivoire, Uganda, Kenya, Mozambique, Angola, India, the United States and more than 20 countries around the world, together with external stakeholders, participated in Run for “TOGETHER WE BUILD A MALARIA-FREE. WORLD” charity campaign.
-
-
- 2,317 million
- Tax payment
-
- 5,885 million
- R&D expenditure for 2022 (including capitalized expenditures)
-
- 38,399
- Global job creation
-
- 60.31 million
- public welfare donations in 2022
-
- 15 years
- Published Corporate Social Responsibility Report for
-
- 56.00 million
- severe malaria patients treated with artesunate